{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:29:51Z","timestamp":1789014591416,"version":"build-2803163510"},"reference-count":61,"publisher":"American Association for Cancer Research (AACR)","issue":"12","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009730","name":"EIF | Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-DT-28-18"],"award-info":[{"award-number":["SU2C-AACR-DT-28-18"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"HHS | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["K08CA252174"],"award-info":[{"award-number":["K08CA252174"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA210827"],"award-info":[{"award-number":["CA210827"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Clonal hematopoiesis (CH) at time of autologous stem cell transplant (ASCT) has been shown to be associated with decreased overall survival (OS) and progression-free survival (PFS) in patients with multiple myeloma not receiving immunomodulatory drugs (IMiD). However, the significance of CH in newly diagnosed patients, including transplant ineligible patients, and its effect on clonal evolution during multiple myeloma therapy in the era of novel agents, has not been well studied. Using our new algorithm to differentiate tumor and germline mutations from CH, we detected CH in approximately 10% of 986 patients with multiple myeloma from the Clinical Outcomes in MM to Personal Assessment of Genetic Profile (CoMMpass) cohort (40\/529 transplanted and 59\/457 non-transplanted patients). CH was associated with increased age, risk of recurrent bacterial infections and cardiovascular disease. CH at time of multiple myeloma diagnosis was not associated with inferior OS or PFS regardless of undergoing ASCT, and all patients benefited from IMiD-based therapies, irrespective of the presence of CH. Serial sampling of 52 patients revealed the emergence of CH over a median of 3 years of treatment, increasing its prevalence to 25%, mostly with DNMT3A mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Using our algorithm to differentiate tumor and germline mutations from CH mutations, we detected CH in approximately 10% of patients with newly diagnosed myeloma, including both transplant eligible and ineligible patients. Receiving IMiDs improved outcomes irrespective of CH status, but the prevalence of CH significantly rose throughout myeloma-directed therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-23-0093","type":"journal-article","created":{"date-parts":[[2023,11,29]],"date-time":"2023-11-29T09:33:45Z","timestamp":1701250425000},"page":"2560-2571","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1190-5978","authenticated-orcid":true,"given":"Tarek H.","family":"Mouhieddine","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."},{"name":"4Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8039-4082","authenticated-orcid":true,"given":"Chidimma","family":"Nzerem","sequence":"additional","affiliation":[{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."},{"name":"5Harvard T.H. Chan School of Public Health, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1329-5288","authenticated-orcid":true,"given":"Robert","family":"Redd","sequence":"additional","affiliation":[{"name":"6Department of Data Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6152-3169","authenticated-orcid":true,"given":"Andrew","family":"Dunford","sequence":"additional","affiliation":[{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5995-5202","authenticated-orcid":true,"given":"Matthew","family":"Leventhal","sequence":"additional","affiliation":[{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8025-9850","authenticated-orcid":true,"given":"Romanos","family":"Sklavenitis-Pistofidis","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8616-6607","authenticated-orcid":true,"given":"Sabrin","family":"Tahri","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."},{"name":"7Department of Hematology, Erasmus MC Cancer Centre, Rotterdam, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-6566","authenticated-orcid":true,"given":"Habib","family":"El-Khoury","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5130-9284","authenticated-orcid":true,"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0197-5451","authenticated-orcid":true,"given":"Benjamin L.","family":"Ebert","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5810-1192","authenticated-orcid":true,"given":"Robert J.","family":"Soiffer","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4375-7399","authenticated-orcid":true,"given":"Jonathan J.","family":"Keats","sequence":"additional","affiliation":[{"name":"8Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8687-1232","authenticated-orcid":true,"given":"Shaadi","family":"Mehr","sequence":"additional","affiliation":[{"name":"9Multiple Myeloma Research Foundation, Norwalk, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-3058","authenticated-orcid":true,"given":"Daniel","family":"Auclair","sequence":"additional","affiliation":[{"name":"9Multiple Myeloma Research Foundation, Norwalk, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7361-3092","authenticated-orcid":true,"given":"Irene M.","family":"Ghobrial","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-4413","authenticated-orcid":true,"given":"Adam S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts."},{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."},{"name":"10Division of Hematology, Brigham and Women's Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-9552","authenticated-orcid":true,"given":"Chip","family":"Stewart","sequence":"additional","affiliation":[{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0936-0753","authenticated-orcid":true,"given":"Gad","family":"Getz","sequence":"additional","affiliation":[{"name":"2Harvard Medical School, Boston, Massachusetts."},{"name":"3Broad Institute of MIT and Harvard, Cambridge, Massachusetts."},{"name":"11Cancer Center and Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"2023122004165188300_bib1","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"2023122004165188300_bib2","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2023122004165188300_bib3","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2013.1.478","article-title":"Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies","volume":"2013","author":"Landgren","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2023122004165188300_bib4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"2023122004165188300_bib5","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"2023122004165188300_bib6","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1182\/blood-2007-05-088443","article-title":"New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells","volume":"110","author":"Perez-Persona","year":"2007","journal-title":"Blood"},{"key":"2023122004165188300_bib7","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.3109\/10428194.2013.764419","article-title":"Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study","volume":"54","author":"Cherry","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"2023122004165188300_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J"},{"key":"2023122004165188300_bib9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.20.00437","article-title":"Genomic profiling of smoldering multiple myeloma identifies patients at a high risk of disease progression","volume":"38","author":"Bustoros","year":"2020","journal-title":"J Clin Oncol"},{"key":"2023122004165188300_bib10","doi-asserted-by":"crossref","first-page":"e365","DOI":"10.1038\/bcj.2015.92","article-title":"Interpretation of cytogenetic results in multiple myeloma for clinical practice","volume":"5","author":"Rajan","year":"2015","journal-title":"Blood Cancer J"},{"key":"2023122004165188300_bib11","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023122004165188300_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas \u2013 current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2023122004165188300_bib13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2018.79.3588","article-title":"Clonal hematopoiesis of indeterminate potential","volume":"37","author":"Boettcher","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023122004165188300_bib14","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"2023122004165188300_bib15","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N Engl J Med"},{"key":"2023122004165188300_bib16","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41586-018-0317-6","article-title":"Prediction of acute myeloid leukaemia risk in healthy individuals","volume":"559","author":"Abelson","year":"2018","journal-title":"Nature"},{"key":"2023122004165188300_bib17","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat Med"},{"key":"2023122004165188300_bib18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.stem.2017.07.010","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Stem Cell"},{"key":"2023122004165188300_bib19","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023122004165188300_bib20","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023122004165188300_bib21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023122004165188300_bib22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"2023122004165188300_bib23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1182\/blood.2021013531","article-title":"Association of clonal hematopoiesis with chronic obstructive pulmonary disease","volume":"139","author":"Miller","year":"2022","journal-title":"Blood"},{"key":"2023122004165188300_bib24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood.2022015384","article-title":"TET2-mutant clonal hematopoiesis and risk of gout","volume":"140","author":"Agrawal","year":"2022","journal-title":"Blood"},{"key":"2023122004165188300_bib25","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat Commun"},{"key":"2023122004165188300_bib26","doi-asserted-by":"crossref","first-page":"e612","DOI":"10.1038\/bcj.2017.94","article-title":"High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma","volume":"7","author":"Miller","year":"2017","journal-title":"Blood Cancer J"},{"key":"2023122004165188300_bib27","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"2023122004165188300_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/ng.806","article-title":"A framework for variation discovery and genotyping using next-generation DNA sequencing data","volume":"43","author":"DePristo","year":"2011","journal-title":"Nat Genet"},{"key":"2023122004165188300_bib29","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nbt.2514","article-title":"Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples","volume":"31","author":"Cibulskis","year":"2013","journal-title":"Nat Biotechnol"},{"key":"2023122004165188300_bib30","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","article-title":"Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs","volume":"28","author":"Saunders","year":"2012","journal-title":"Bioinformatics"},{"key":"2023122004165188300_bib31","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1101\/gr.107524.110","article-title":"The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data","volume":"20","author":"McKenna","year":"2010","journal-title":"Genome Res"},{"key":"2023122004165188300_bib32","doi-asserted-by":"crossref","first-page":"e67","DOI":"10.1093\/nar\/gks1443","article-title":"Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation","volume":"41","author":"Costello","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"2023122004165188300_bib33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cels.2018.03.002","article-title":"Scalable open science approach for mutation calling of tumor exomes using multiple genomic pipelines","volume":"6","author":"Ellrott","year":"2018","journal-title":"Cell Syst"},{"key":"2023122004165188300_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nbt.2203","article-title":"Absolute quantification of somatic DNA alterations in human cancer","volume":"30","author":"Carter","year":"2012","journal-title":"Nat Biotechnol"},{"key":"2023122004165188300_bib35","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","article-title":"The ensembl variant effect predictor","volume":"17","author":"McLaren","year":"2016","journal-title":"Genome Biol"},{"key":"2023122004165188300_bib36","doi-asserted-by":"crossref","first-page":"E2423","DOI":"10.1002\/humu.22771","article-title":"Oncotator: cancer variant annotation tool","volume":"36","author":"Ramos","year":"2015","journal-title":"Hum Mutat"},{"key":"2023122004165188300_bib37","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ajhg.2012.09.004","article-title":"Detecting and estimating contamination of human DNA samples in sequencing and array-based genotype data","volume":"91","author":"Jun","year":"2012","journal-title":"Am J Hum Genet"},{"key":"2023122004165188300_bib38","doi-asserted-by":"crossref","first-page":"D840","DOI":"10.1093\/nar\/gkw971","article-title":"The ExAC browser: displaying reference data information from over 60\u2009000 exomes","volume":"45","author":"Karczewski","year":"2017","journal-title":"Nucleic Acids Res"},{"key":"2023122004165188300_bib39","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"2023122004165188300_bib40","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"key":"2023122004165188300_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nbt.1754","article-title":"Integrative genomics viewer","volume":"29","author":"Robinson","year":"2011","journal-title":"Nat Biotechnol"},{"key":"2023122004165188300_bib42","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41592-018-0036-9","article-title":"DeTiN: overcoming tumor-in-normal contamination","volume":"15","author":"Taylor-Weiner","year":"2018","journal-title":"Nat Methods"},{"key":"2023122004165188300_bib43","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1182\/bloodadvances.2021004554","article-title":"Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy","volume":"5","author":"Miller","year":"2021","journal-title":"Blood Adv"},{"key":"2023122004165188300_bib44","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"2023122004165188300_bib45","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41591-021-01371-0","article-title":"Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection","volume":"27","author":"Zekavat","year":"2021","journal-title":"Nat Med"},{"key":"2023122004165188300_bib46","doi-asserted-by":"crossref","first-page":"5975","DOI":"10.1038\/s41467-021-26138-6","article-title":"Clonal hematopoiesis is associated with risk of severe Covid-19","volume":"12","author":"Bolton","year":"2021","journal-title":"Nat Commun"},{"key":"2023122004165188300_bib47","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1182\/blood.2022018052","article-title":"Clonal hematopoiesis of indeterminate potential and risk of death from COVID-19","volume":"140","author":"Miller","year":"2022","journal-title":"Blood"},{"key":"2023122004165188300_bib48","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"2023122004165188300_bib49","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"key":"2023122004165188300_bib50","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"key":"2023122004165188300_bib51","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol"},{"key":"2023122004165188300_bib52","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41375-021-01431-x","article-title":"Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial","volume":"36","author":"Leypoldt","year":"2022","journal-title":"Leukemia"},{"key":"2023122004165188300_bib53","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","article-title":"Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy","volume":"24","author":"Cowan","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023122004165188300_bib54","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"key":"2023122004165188300_bib55","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"key":"2023122004165188300_bib56","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","volume":"140","author":"Sperling","year":"2022","journal-title":"Blood"},{"key":"2023122004165188300_bib57","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41586-022-04785-z","article-title":"The longitudinal dynamics and natural history of clonal haematopoiesis","volume":"606","author":"Fabre","year":"2022","journal-title":"Nature"},{"key":"2023122004165188300_bib58","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41586-022-04786-y","article-title":"Clonal dynamics of haematopoiesis across the human lifespan","volume":"606","author":"Mitchell","year":"2022","journal-title":"Nature"},{"key":"2023122004165188300_bib59","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/bloodadvances.2019000731","article-title":"Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias","volume":"3","author":"Sridharan","year":"2019","journal-title":"Blood Adv"},{"key":"2023122004165188300_bib60","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41467-018-02858-0","article-title":"Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential","volume":"9","author":"Wong","year":"2018","journal-title":"Nat Commun"},{"key":"2023122004165188300_bib61","first-page":"2359","article-title":"Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures","volume-title":"Blood","author":"Diamond","year":"2023"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-23-0093\/3387798\/crc-23-0093.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2560\/3391947\/crc-23-0093.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/12\/2560\/3391947\/crc-23-0093.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T23:17:21Z","timestamp":1703027841000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/12\/2560\/731741\/Clinical-Outcomes-and-Evolution-of-Clonal"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":61,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,18]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-23-0093","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.24851022.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850995","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851019","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851016.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850971","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851013","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850983","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851013.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851019.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850971.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850977","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850989","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851010.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851004.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850968.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851010","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851001.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851022","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850986","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850998","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850974","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850989.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851016","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850980","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850992","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851004","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850968","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850998.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850992.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850995.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850974.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850977.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24851001","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850986.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850983.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.24850980.v1","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.6986089","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6986089.v1","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}